Johnson & Johnson Aktie News

Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals.

LOS ANGELES--(BUSINESS WIRE)--A Los Angeles Superior Court jury today delivered a $40 million verdict against Johnson & Johnson. The trial featured two California women who developed ovarian cancer after decades of using the company's talc-based baby powder products. The award to plaintiffs Monica Kent and Deborah Schultz, and her husband, Dr. Albert Schultz, totals $40 million in compensatory ...

A California jury on Friday awarded $40 million to two women who said Johnson & Johnson's baby powder was to blame for their ovarian cancer.

Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with BRCA2-mutated mCSPC HORSHAM, Pa. , Dec. 12, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA...

A notable bank and a major investment management firm bought more shares of Johnson & Johnson. The healthcare giant has performed well this year despite some significant headwinds.

Johnson & Johnson has surged 14% since my last update, surpassing my $188 target, and now trades near $200. Top-line growth is accelerating, but revenue expansion remains below industry rates and is partially priced in after a strong rally. JNJ's capital structure remains leveraged, clouding its outlook despite progress in positioning for future success.

For investors approaching or in retirement, the right stock portfolio balances reliable income, low volatility, and consistent dividend growth.

The US Equity Income Fund underperformed its benchmark, the Russell 1000 Value Index, net of fees during the third quarter. Enterprise software company, Oracle Corporation, was a top contributor to relative returns during the quarter. Our position in consumer healthcare company, Kenvue Inc., was a top detractor from relative performance during the month.